Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

被引：0

作者：

Tombal, B. ^{[1
]}

Smith, M. R. ^{[2
]}

Hussain, M. ^{[3
]}

Saad, F. ^{[4
]}

Fizazi, K. ^{[5
]}

Sternberg, C. N. ^{[6
]}

Crawford, E. D. ^{[7
]}

Kapur, S. ^{[8
]}

Zhang, W. ^{[9
]}

Ploeger, B. ^{[10
]}

Li, R. ^{[11
]}

Kuss, I. ^{[12
]}

Zieschang, C.

Wittemer-Rump, S.

Rezazadeh, Kalebasty A. ^{[13
]}

机构：

[1] Clin Univ St Luc, Dept Urol, Brussels, Belgium

[2] Massachusetts Gen Hosp Canc Ctr, Dept Oncol, Boston, MA USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[4] Univ Montreal, Dept Urol, Hosp Ctr, Montreal, PQ, Canada

[5] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France

[6] Englander Inst Precis Med, Weill Cornell Dept Med, New York, NY USA

[7] Univ Calif San Diego, Dept Urol, Sch Med, San Diego, CA USA

[8] Bayer SEA, Dept Med Affairs, Singapore, Singapore

[9] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA

[10] Bayer AG, Clin Pharmacol, Berlin, Germany

[11] Bayer Healthcare Pharmaceut Inc, Dept Stat, Whippany, NJ USA

[12] Bayer AG, Clin Dev, Berlin, Germany

[13] Univ Calif Irvine, Div HematologyOncol, Orange, CA USA

来源：

EUROPEAN UROLOGY | 2023年 / 83卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A1184

引用

页数：2

共 50 条

[31] Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC)
Shore, Neal D.
Ross, Ashley
Preston, Mark A.
Gregg, Justin R.
Salami, Simpa Samuel
Bruno, Amanda
Srinivasan, Shankar
Constantinovici, Niculae
Ortiz, Jorge A.
Littleton, Natasha
Verholen, Frank
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey M.
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Yakovlevich
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
Jiang, W.
Qu, S.
Liu, Y.
Yao, X.
Liu, M.
ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
[34] RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS
Saad, Fred
Tombal, Bertrand
Hussain, Maha
Fizazi, Karim
Sternberg, Cora N.
Crawford, E. David
Nordquist, Luke T.
Tutrone, Ronald
Shore, Neal D.
Belkoff, Laurence
Kapur, Shivani
Jhaveri, Jay
Ortiz, Jorge
Srinivasan, Shankar
Verholen, Frank
Smith, Matthew R.
JOURNAL OF UROLOGY, 2023, 209 : E380 - E380
[35] Adding Docetaxel to Androgen-Deprivation Therapy in Newly Diagnosed Metastatic Prostate Cancer
Vogelzang, Nicholas J.
AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (03) : 10 - 11
[36] The Addition of Darolutamide to Androgen Deprivation Therapy and Docetaxel in a 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
Crawford, David
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07)
[37] Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer
Hammerer, P.
Manka, L.
UROLOGE, 2019, 58 (10): : 1185 - 1197
[38] Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).
Shore, Neal D.
Preston, Mark A.
Gregg, Justin R.
Salami, Simpa Samuel
Ross, Ashley
Bruno, Amanda
Srinivasan, Shankar
Constantinovici, Niculae
Ortiz, Jorge A.
Adorjan, Patrick
Verholen, Frank
Mckay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[39] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
Vaishampayan, U. N.
Heilbrun, L.
Monk, P.
Sonpavde, G.
Tejwani, S.
Heath, E. I.
Fontana, J.
Chinni, S.
ANNALS OF ONCOLOGY, 2018, 29
[40] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
Shore, Neal D.
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Gomez-Veiga, Francisco
Rosbrook, Brad
Lee, Ho-Jin
Haas, Gabriel P.
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →